Form 4: Kairos Pharma CFO Doug Samuelson Acquires 2,500 Shares

Kairos Pharma's Chief Financial Officer, Doug Samuelson, purchased 2,500 shares of common stock at $1.50 per share on November 22, 2024.

Summary

• Doug Samuelson, the Chief Financial Officer of Kairos Pharma, acquired 2,500 shares of the company's common stock.
• The transaction occurred on November 22, 2024.
• The purchase price was $1.50 per share.
• Following the transaction, Mr. Samuelson directly owns 60,796 shares of Kairos Pharma common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive as insider buying can be seen as a sign of confidence, but the transaction is not large enough to be a major market mover.

Positives

• The purchase of shares by a company officer can be seen as a positive sign of confidence in the company's future.

Industry Context

Insider trading activity is closely monitored by regulators and investors as it can provide insights into management's view of the company's prospects.

Comparison to Industry Standards

• SEC Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders.
• The transaction is relatively small in terms of the number of shares purchased, but it is still a relevant disclosure.

Stakeholder Impact

• The share purchase may have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Kairos Pharma, Doug Samuelson, insider trading, share purchase, common stock, CFO, KAPA